VogenX

News

Three more biotechs have revealed their intentions to list on Nasdaq - BlossomHill, VogenX, and Latigo - as 2026 heads for a record IPO haul.

News

Lundbeck has completed patient randomisation in a pivotal trial of epilepsy candidate bexicaserin, one of its major growth hopes.

Digital

A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.